Table 2

Association of velocity* or doubling time† with prostate cancer mortality among men with PSA failure and pertinent data (N=233; see text for details)

HRp Value95% CI
Surgery patients (N=78)
 High velocity4.20.0371.1 to 16.4
 Fast doubling time1.00.950.27 to 4.0
Radiation therapy patients (N=155)
 High velocity3.80.190.52 to 27.7
 Fast doubling time2.40.0491.0 to 5.8
  • *Calculation of ≥1.0 ng/mL/year used to define high velocity.

  • †Calculation of ≤12 months used to define fast doubling time.

  • PSA, prostate-specific antigen.